Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10190225" target="_blank" >RIV/00216208:11110/13:10190225 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14740/13:00069041 RIV/65269705:_____/13:#0002130 RIV/00064165:_____/13:10190225
Result on the web
<a href="http://dx.doi.org/10.3324/haematol.2013.086355" target="_blank" >http://dx.doi.org/10.3324/haematol.2013.086355</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2013.086355" target="_blank" >10.3324/haematol.2013.086355</a>

Result language
angličtina
Original language name
Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia
Original language description
Nilotinib, a 2nd generation tyrosin kinase inhibitor (TKI), is efficacious in the treatment of chronic myelogenous leukemia (CML). Impaired glucose metabolism with hyperglycemia represents one of the most frequently observed adverse events (AEs) during nilotinib therapy. However, the mechanism of glucose metabolism impairment remains unknown.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FB - Endocrinology, diabetology, metabolism, nutrition
OECD FORD branch
—

Project
<a href="/en/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: Central european institute of technology</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)